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Studies by van Loosdregt et al. and Chen et al. in this issue of Immunity provide evidence for previously
unrecognized players that regulate FOXP3 degradation. These are interesting developments that point to
unappreciated mechanisms by which inflammatory signals can impact expression of FOXP3 and possibly
the stability of Treg cell phenotypes.An essential aspect of the vertebrate
immune response is the requirement
for peripheral tolerance. An immune
response that, by its nature, is self-reac-
tive and poised to respond needs to be
held in check and to not damage host
tissues. There are multiple mechanisms
that contribute to peripheral tolerance,
and many types of immune cells can
acquire regulatory properties in a contex-
tual manner; however, one unquestion-
ably critical component is regulatory T
(Treg) cells. It has been a decade since
the discovery that the forkhead transcrip-
tion factor FOXP3 is critical for Treg cell
development and homeostasis. Although
other factors also contribute to Treg cell
integrity, there is general agreement that
FOXP3 is essential for tolerance, a fact
that is vividly illustrated in both mice and
humans by the severe autoimmune dis-
ease associated with the absence of
FOXP3 and Treg cells. Elucidating how
easily Foxp3 expression is or is not extin-
guished and defining populations of
FOXP3-expressing cells that represent
distinct, stable ‘‘lineages’’ remain topics
of ongoing study. In this issue of Immu-
nity, studies by van Loosdregt et al.
(2013) and Chen et al. (2013) point tonew mechanisms through which this key
transcription factor can be degraded.
These studies reveal previously unrecog-
nized pathways that control FOXP3
protein expression in response to inflam-
matory stimuli and how the disruption of
these pathways impact Treg-cell-medi-
ated immune suppression.
First, in order to put these papers in
context, it is worth reviewing that, in
the mouse, two general types of FOXP3-
expressing Treg cells exist (Abbas
et al., 2013). Thymic Treg (also termed
natural or nTreg) cells are generated in
a T cell-receptor-dependent manner.
Under normal conditions, and in the
setting of some infections and autoim-
mune disease, nTreg cells appear to
have relatively stable expression of
FOXP3, the Foxp3 locus being fully deme-
thylated (Floess et al., 2007; Miyao et al.,
2012; Rubtsov et al., 2010). FOXP3 can
also be induced by cytokines, especially
IL-2 and TGF-b—such regulatory cells
are referred to as induced or iTreg cells
and are generated under normal condi-
tions at mucosal barriers. These cells
have more flexible FOXP3 expression,
the Foxp3 locus being incompletely
demethylated. Whether iTreg cells canlose FOXP3 expression and may become
pathogenic is not under debate. However,
whether there is a definable stable lineage
of Treg cells that permanently expresses
FOXP3 and always maintains its suppres-
sor phenotype irrespective of the host
environment has been the topic of con-
siderable investigation. The practical
implication is that, if we can isolate or
create such a population, then these
cells could be effective therapies for
autoimmune disease and allotransplan-
tation. Indeed, several clinical trials are
underway.
In the nTreg cell plasticity camp, several
groups have reported that ‘‘stable’’ Treg
cells can lose FOXP3 expression in the
setting of inflammation (Oldenhove et al.,
2009; Zhou et al., 2009). This has been
documented either directly by the mea-
surement of FOXP3 expression with
intracellular staining or indirectly with
different Foxp3 reporter mice. Typically,
the loss of FOXP3 is associated with
the acquisition of the capacity to produce
effector cytokines. Challenging these
conclusions, rival groups have drawn
opposite conclusions with similar reporter
mice (Miyao et al., 2012; Rubtsov et al.,
2010). Supporting their work is the, August 22, 2013 ª2013 Elsevier Inc. 201
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Figure 1. New Players in the Posttranslational Regulation of FOXP3 Stability in the Setting of
Inflammation
Chen et al. (2013) and van Loosdregt et al. (2013) provide evidence for Stub1 and USP7—two factors
that control amounts of FOXP3 by influencing ubiquitination and proteasomal degradation. In investigating
means by which inflammatory signals downregulate FOXP3 protein, Chen et al. (2013) note that
these stimuli induce Stub1; in conjunction with its partner, HSP-70, Stub1 promotes FOXP3 ubiquiti-
nation and degradation. In contrast, van Loosdregt et al. (2013) identify another player, USP7, that
deubiquitinates FOXP3 and impedes its degradation. Normally, Treg cells express USP7, but IL-6 inhibits
its expression. Loss of USP7 accelerates FOXP3 degradation.
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Previewsrealization that not all nTreg cells are truly
thymically derived, and small numbers
of contaminating, peripherally generated
iTreg cells may be responsible for the
discrepancy (Miyao et al., 2012; Weiss
et al., 2012). Furthermore, it has been
appreciated that the expression of
FOXP3 alone is not sufficient to maintain
Treg cell integrity; in addition to FOXP3,
extrinisic factors are important, as illus-
trated by the role of IL-2 receptor (Miyao
et al., 2012) along with other possible
intrinsic factors, including Neuropilin 1
(NRP1) (Weiss et al., 2012). Thus, the
isolation and investigation of CD25+
NRP1+ FoxP3+ nTreg cells has cemented
the orthodoxy that stable nTreg cells exist
and that this stability is critically depen-
dent on the methylation status of the
Foxp3 gene locus (Sakaguchi et al., 2013).
The two studies in this issue of
Immunity shed new light on mechanisms
that control FOXP3 expression. Impor-
tantly, the focus is not the transcriptional
or epigenetic regulation of Foxp3; rather,
they investigate how Treg cell stability
might be influenced by factors that
impact FOXP3 protein (Figure 1). Though
not definitively established, especially
with respect to in vivo control, the findings
nonetheless may provide another way of
thinking about FOXP3 stability and Treg
cell plasticity. The basic finding by Chen
et al. (2013) is that inflammatory stimuli202 Immunity 39, August 22, 2013 ª2013 Elsresult in Myd88- and proteasome-depen-
dent degradation of FOXP3 in transfected
Jurkat cells as well as primary mouse
and human Treg cells. The authors used
mass spectrometry to find FOXP3 part-
ners and identify Hsp70. They note that
Hsp70 associates with the stress-acti-
vated E3 ubiquitin ligase Stub1 and
show that these proteins bind and pro-
mote Foxp3 K48 ubiquitination. Knocking
down Stub1 and Hsp70 prevents the
degradation of FOXP3 protein, and,
conversely, the generation of Foxp3
mutants that do not bind these factors
are resistant to degradation.
van Loosdregt et al. (2013) looked at the
other side of the coin, identifying factors
that preserve FOXP3 protein. The present
study starts off by using a deubiquiti-
nation (DUB) inhibitor, which inhibits
in vitro and in vivo suppressive activity of
Treg cells. Consistent with the findings
of Chen et al. (2013), the Coffer group’s
previous work and the current van Loos-
dregt et al. (2013) study also show that
FOXP3 is ubiquitinated and degraded in
a proteasome-dependent manner. Using
mass spectrometry, the authors identify
ubiquitination sites on FOXP3 and also
identify USP7 as a DUB prominently
expressed in Treg cells. They go on to
provide evidence that FOXP3 is a sub-
strate of USP7 and that USP7 regulates
FOXP3 turnover in transfected cells. Theevier Inc.authors also show that USP7 levels are
reduced by inflammatory stimuli, and
this correlates with a reduction in FOXP3
protein levels. Functionally, they show
that knocking down USP7 interferes with
Treg cell function.
The strength of both studies is that they
provide evidence of previously unrecog-
nized modes of regulating FOXP3. Both
studies provide provocative biochemical
data and reasonably solid in vitro data.
Given that the mechanism of action is
posttranslational, it is unlikely that nTreg
cells will be spared any more than iTreg
cells, and much of the work by Chen
et al. (2013) was performed with nTreg
cells, albeit ones that were isolated with
simple expression of CD25. It is likely
that future work will focus on subsets
of Treg cells and other factors that
influence susceptibility to degradation.
Additionally, these are not the only
studies to invoke FOXP3 ubiquitination
as a regulatory mechanism. That is,
metabolic factors also control Treg cell
function and expression of Foxp3.
HIF-1a has been shown to inhibit
FOXP3 through ubiquitination (Dang
et al., 2011), and, like Stub1, HIF-1a is
induced by IL-6 in conjunction with T cell
receptor stimulation. However, Chen
et al. (2013) show that HIF-1a is not
required for lipopolysaccharide (LPS)-
induced Foxp3 downmodulation in Treg
cells, suggesting that the LPS- and
Stub1-mediated FOXP3 depletion is
distinct from the process previously
observed under hypoxic stress (Dang
et al., 2011). As a corollary, van Loosdregt
et al. (2013) noted that IL-6 inhibits USP7
protein expression, further inhibiting the
stability of FOXP3.
The biggest limitations of both studies
pertain to the in vivo data. Using the
T cell transfer colitis model, the authors
of both studies link the function of Stub1
and USP7 to Treg cell integrity. That is,
Stub1 overexpression and USP7 knock-
down interfere with Treg cell function in
this standard model. Ideally, in the future,
we will learn more definitively what the
consequences are of specific Treg cell
deletion of Stub1, Hsp70, and USP7.
The use of fate mapping models and of
additional markers have been important
in trying to sort out bona fide ex-Tregs
from cells that arise as nTreg versus
iTreg cells; clearly, these strategies will
be employed in order to understand
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Previewswhat circumstances are associated
with proteasome-dependent degradation
of FOXP3. Whether the findings of the
present papers speak more to the pre-
vention of maximal induction of FOXP3
or the effective loss of FOXP3 in fully
differentiated nTreg cells remains to be
established.
Regardless, the implication that inflam-
matory cytokines can strip FOXP3 from a
Treg cell does not simply provide more
fuel for an academic fire; what makes
this work of real clinical importance is
the possibility of manipulating FOXP3
and Treg cells in autoimmunity and trans-
plantation. Conversely, the therapeutic
utility of attenuating regulatory immune
mechanisms is one of the most exciting
developments in cancer immunology.
Both groups were mindful in demon-
strating that ubiquitination is equally as
important in human andmurine Treg cells.
Proteasome inhibitors are already usedin the treatment of myeloma and mantle
cell lymphoma, and it may not be long
before they are used in the regulation of
autoimmune disease.REFERENCES
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Pathogen-induced inflammation modulates CD8 T cell effector and memory differentiation. In this issue of
Immunity, Plumlee et al. (2013) demonstrate that clonally distinct CD8 T cells have the ability to generate
numerous types of effector cell fates based on extrinsic pathogen-induced environmental cues.During infection, individual naive path-
ogen-specific T cells receive signals that
incite exponential growth and effector
differentiation in order to rid the body of
the pathogen. After pathogen clearance,
most of the effector T cells undergo
apoptosis, but a small proportion of cells
survive to differentiate into mature mem-
ory T cells that, together with long-lived
plasma cells and memory B cells, provide
protection upon reinfection. As effector
CD8 T cells expand and differentiate,
they give rise to numerous phenotypically,functionally, and anatomically distinct
subsets, which in turn give rise to diverse
pools of memory CD8 T cells. Some
effector cell subsets are inherently more
fit to persist long-term and populate the
memory cell pool, and in many cases
these cells can be identified based on
increased expression of interleukin-7Ra
(IL-7Ra, CD127), CD27, and B cell lym-
phoma 2 (Bcl2) (Kaech and Cui, 2012).
Understanding the basis of diversity in
effector CD8 T cell function, migration,
and memory cell potential might helpinform the generation of more efficacious
vaccines against pathogens and cancers.
In the current issue of Immunity, Plumlee
et al. (2013) establish that extrinsic path-
ogen-induced environmental cues shape
the differentiation of individual naive CD8
T cell clones during infection.
T cell effector and memory differentia-
tion is influenced by the type, timing,
strength, and duration of antigenic (signal
1), costimulatory (signal 2), and cytokine
(signal 3) signaling. Different infections
modulate these signals by infecting, August 22, 2013 ª2013 Elsevier Inc. 203
